Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term BRCA1. Found 20 abstracts

Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 Mar;148(3):507-14.
Handorf E, Crumpler N, Gross L, Giri VN. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal of Genetic Counseling. 2014 Jun;23(3):371-6.   PMCID: PMC4028414
Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Paligo M, Aretini P, Kantala J, Aroer B, Von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M, Benitez J, Gilbert M, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AM, Seynaeve C, van der Luijt RB, Devilee P, Easton DF, Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson O, Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P, Durocher F, Chenevix-Trench G, Beesley J, Chen X, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J. Association of PHB 1630 C > T and MTHFR 677 C > T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer. 2012 Jun;106(12):2016-24.   PMCID: PMC3388557
Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genetics in Medicine. 2010 May;12(5):245-59.   PMCID: not NIH funded
Apicella C, Peacock SJ, Andrews L, Tucker K, Daly MB, Hopper JL. Measuring, and identifying predictors of, women's perceptions of three types of breast cancer risk: population risk, absolute risk and comparative risk. British Journal of Cancer. 2009 Feb;100(4):583-9.   PMCID: PMC2653735
Melnikov A, Scholtens D, Godwin A, Levenson V. Differential Methylation Profile of Ovarian Cancer in Tissues and Plasma. Journal of Molecular Diagnostics. 2009 Jan;11(1):60-5.   PMCID: PMC2607567
Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White M, Artioli G, Dudlicek L, Olopade OL. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine. 2008 Mar;10(3):161-6.
Apicella C, Dowty JG, Dite GS, Jenkins MA, Senle RT, Daly MB, Andrulis IL, John EM, Buys SS, Li FP, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, Southey MC, Foulkes WD, Hopper JL. Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clinical genetics. 2007 Aug;72(2):87-97.
Apicella C, Peacock SJ, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL. Determinants of preferences for genetic counselling in Jewish women. FAMILIAL CANCER. 2006 Jan;5(2):159-67.
Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecologic Oncology. 2006 Nov;103(2):719-28.
Chen XW, Arciero CA, Godwin AK. BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance. EXPERT REVIEW OF ANTICANCER THERAPY. 2006 Feb;6(2):187-96.
Chen XW, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK. Intronic alterations in BRCA1 and BRCA2: Effect on mRNA splicing fidelity and expression. HUMAN MUTATION. 2006 May;27(5):427-35.
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. International journal of cancer. 2006 May;118(9):2281-4.
Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes & Control. 2005 Aug;16(6):667-74.
Whittemore AS, Balise RR, Pharoah PD, DiCioccio RA, Oakley-Girvan I, Ramus SJ, Daly M, Usinowicz MB, Garlinghouse-Jones K, Ponder BA, Buys S, Senie R, Andrulis I, John E, Hopper JL, Piver MS. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British Journal of Cancer. 2004 Nov 29;91(11):1911-5.
Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS, Cooperative Family Registry Breast. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Human Mutation. 2002 Jan;20(1):65-73.
Hamilton TC, Berek JS, Kaye SB. Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future?. Annals of Oncology. 1999 Jan;10:69-73.
Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. British Journal of Cancer. 1999 Sep;81(1):179-83.
Liede A, Tonin PN, Sun CC, Serruya C, Daly MB, Narod SA, Foulkes WD. Is hereditary site-specific ovarian cancer a distinct genetic condition?. American Journal of Medical Genetics. 1998 Jan 06;75(1):55-8.
Shoda Y, Mischel W, Miller SM, Diefenbach M, Daly MB, Engstrom PF. Psychological interventions and genetic testing: Facilitating informed decisions about BRCA1/2 cancer susceptibility. Journal of Clinical Psychology in Medical Settings. 1998 Mar;5(1):3-17.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term BRCA1

BRCA1 BRCA2 breast cancer susceptibility breast-cancer Genetics & Heredity gene ovarian-cancer women risk decision-making CARRIERS genes colorectal-cancer genetic counselling dna-damage response families Ashkenazi Oncology FAMILY-HISTORY ovarian population OVARIAN-CANCER expression information history ovarian cancer WOMEN chromatin remodeling EMD protein interaction BREAST behavioral medicine RISK CARCINOMAS NMD patient outcomes HORMONE REPLACEMENT THERAPY aberrant transcript radiation resistance cells DETERMINANTS two-dimensional gene scanning rna personality SUSCEPTIBILITY GENES HOXB13 ASSOCIATION brca1 mutations 2 mutations consultations BREAST-CANCER RISK prevention tamoxifen ovarian cancer risk age at menarche coping styles randomized trial Results No statistically significant difference in frequency of these prophylactic salpingo-oophorectomy site-specific ovarian cancer GENES with BRCA1 Genetic mutations BRCA2 genotypes or are molecular testing genetic scanning tests SURGERY GERMLINE MUTATIONS INCREASED RISK etiological factor we have investigated a recent cancer precursors is controversial Here hereditary breast women age 45-54 of either HR or NR groups early-life cancer sporadic breast-cancer samples MICE unknown susceptibility genes bilateral prophylactic oophorectomy signal peptidase stratification were assessed in a blinded fashion frequency family communication breast cancer risk inclusion cysts and deep invaginations were found much more commonly in surgical adjuvant Prostate cancer deletion PREVALENCE estrogen-receptor status p53 gene reproductive modifiers CA125 2 genotypes or reproductive history variants of unknown significance cost CANCER-RISK heterozygosity 185DELAG nonsense t4 endonuclease-vii OVULATION allele loss chromosome-17 cell-cycle sequence ROSE PROMOTER TUMORIGENESIS ULTRASOUND reproductive factors Family history GONADOTROPINS AB Objective From analysis of pre-cancer ovarian tissues obtained from high familial risk TUMORS Ovarian cancer ovaries from surgeries due to other non-ovarian-related cancer or ovarian tumours 20-year follow-up Veliparib carcinogenesis MANAGEMENT prose-study-group tp53 ashkenazi-jewish individuals polymorphism oophorectomy mutation carriers SSCP ovarian cancer oral contraceptives folate status several studies reported the increased prophylactic oophorectomies identification 185delAG cancer (c) 2006 Elsevier Inc All rights reserved collection of ovaries from prophylactic oophorectomies and control genetic testing suppressor satisfaction aging ubiquitination PHB 1630 C > T polymorphism 2 mutation carriers-MTHFR 677 C > T polymorphism-breast epithelium carcinomas hereditary ovarian cancer
Last updated on Wednesday, February 05, 2020